Yijie Liko Therapeutics Honored in 2024 VENTURE50 New Sprout Top 50 and Healthcare Top 50, Files IPO Prospectus
Epigenic
Gene Editing Technology Developer
January 9, 2025, the results of the 2024 VENTURE50评选 initiated by Zero2IPO Group (1945.HK) and Investment界 have been officially announced. Amidst fierce competition,Xingbei·FTO No.1 Park Enterprise Epigenic Therapeutics, Inc. Achieves Innovative Breakthroughs in the Field of Epigenetics, Honored to be"Top 50 Rising Stars 2024" and "Top 50 in Healthcare 2024", becoming a rising star in the healthcare field.
VENTURE50The selection aims to discover and support science and technology innovation enterprises with high growth potential. Since its establishment, Epigenic has been committed to the research and development of cutting-edge technologies and innovative applications in the healthcare field, receiving extensive attention and recognition from the capital market. Being selected as one of the top 50 on the New Bud List is not only a high affirmation of Epigenic's innovation capabilities but also injects strong confidence and momentum into the company’s future development.
In the healthcare industry rankings, Epigenic also performed excellently. As an innovative pioneer in the biopharmaceutical field, the company has gained high recognition from the review experts with its leading technology in epigenetic drug research and development. Being selected as one of the top 50 in healthcare further consolidates Epigenic's leading position in the industry.Currently, the company is accelerating the development of its core candidate drug, EPI-003 (a treatment for hepatitis B), with plans to launch the world's first clinical trial based on epigenetic regulation for chronic hepatitis B in the first quarter of 2025.
VENTURE50, initiated by Zero2IPO Group (1945.HK) in 2006, has successfully held 19 sessions so far and become a benchmark for investment in high-growth enterprises in China. Since its inception, more than 79,000 companies have participated in the selection, helping the selected enterprises raise over 312.325 billion RMB. The follow-up financing rate is 57.02%, and the listing rate is 10.23%. Epigenic Therapeutics, Inc.'s recognition on dual lists this time marks that its innovation capability and investment value in the healthcare field have been widely acknowledged.
Looking ahead, Epigenic stated that it will continue to uphold the spirit of innovation, join hands with partners, and jointly promote the high-quality development of the healthcare industry, contributing more to the cause of human health.
About Epigenic
Epigenic Therapeutics, Inc. is a cutting-edge biotechnology company dedicated to treating various diseases through epigenetic regulation and developing the next generation of gene modulation therapies. Founded in 2021 by a group of scientists specializing in gene modulation technology and seasoned experts from the pharmaceutical development industry, the company has established multiple pipeline candidates covering metabolic, cardiovascular, viral hepatitis, ophthalmology, and rare disease fields.
About SimbayPark
Shanghai FT1 Life Science Park (Abbreviation"Simbay Park, Star North · Free Trade Zone No.1") is located in the Waigaoqiao Bonded Area, the core of Shanghai's Pudong New Area Free Trade Zone. It is an innovative service-oriented characteristic industrial park under the Star North Group, focusing on the incubation, cultivation, and transformation of medical enterprises.The park relies on the unique "FTAs + bonded" outward-oriented economic regional advantages, and through gathering the whole industry chain service resources of CRO+CDMO+CSO+EHS in biopharmaceuticals, government innovation and entrepreneurship support policies, and many well-known investment institutions, provides enterprises with truly in-depth technical incubation in the medical industry. It serves as a steward for enterprises in the transformation of technical achievements, and strives to create an international biopharmaceutical industry innovation and entrepreneurship base.
